MMI Co-Founder, John Hipp, PhD to be Guest Editor for Special Issue of Bioengineering! Submit by 01/31/27!
Medical Metrics, Inc. is proud to have worked with Optinose on their ReOpen clinical trials, which have recently received FDA approval! A heartfelt thank you to all our amazing collaborators, including our dedicated neuroradiologist readers, Key Opinion Leader consultants, and the incredible project personnel on both teams!
FDA recommends using imaging of the sinuses as a secondary efficacy endpoint for drugs being developed to treat chronic rhinosinusitis with nasal polyps (CRSwNP).
Semi-automated quantitative measurements of sinus inflammation from 3D CT imaging correlate well with clinical outcomes.
